(R)-6-(2-Benzylpyrrolidin-1-yl)-4-morpholinopyridin-2(1H)-one

ID: ALA4873212

PubChem CID: 155884468

Max Phase: Preclinical

Molecular Formula: C20H25N3O2

Molecular Weight: 339.44

Molecule Type: Unknown

Associated Items:

This compound is not in our inventory system

Names and Identifiers

Canonical SMILES:  O=c1cc(N2CCOCC2)cc(N2CCC[C@@H]2Cc2ccccc2)[nH]1

Standard InChI:  InChI=1S/C20H25N3O2/c24-20-15-18(22-9-11-25-12-10-22)14-19(21-20)23-8-4-7-17(23)13-16-5-2-1-3-6-16/h1-3,5-6,14-15,17H,4,7-13H2,(H,21,24)/t17-/m1/s1

Standard InChI Key:  NUUYFIBMHLLMSL-QGZVFWFLSA-N

Molfile:  

 
     RDKit          2D

 25 28  0  0  0  0  0  0  0  0999 V2000
   21.5318  -17.0413    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   21.5318  -17.8626    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   22.2412  -18.2712    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   22.9506  -17.8626    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   22.9506  -17.0413    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   22.2412  -16.6286    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   23.6614  -18.2753    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   23.6582  -19.0975    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   24.3613  -19.5071    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   25.0761  -19.1030    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   25.0792  -18.2807    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   24.3676  -17.8625    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   24.3560  -20.3242    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   25.7893  -17.8762    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   26.5320  -18.2106    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   27.0823  -17.6065    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   26.6778  -16.8964    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   25.8775  -17.0618    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   26.6980  -19.0108    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   27.4739  -19.2671    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   27.6381  -20.0675    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   28.4132  -20.3240    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   29.0242  -19.7799    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   28.8548  -18.9761    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   28.0799  -18.7234    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
  1  2  1  0
  1  6  1  0
  2  3  1  0
  3  4  1  0
  4  5  1  0
  5  6  1  0
  7  8  2  0
  7 12  1  0
  8  9  1  0
  9 10  1  0
 10 11  1  0
 11 12  2  0
  4  7  1  0
  9 13  2  0
 11 14  1  0
 14 15  1  0
 15 16  1  0
 16 17  1  0
 17 18  1  0
 18 14  1  0
 15 19  1  6
 19 20  1  0
 20 21  2  0
 21 22  1  0
 22 23  2  0
 23 24  1  0
 24 25  2  0
 25 20  1  0
M  END

Alternative Forms

  1. Parent:

    ALA4873212

    ---

Associated Targets(Human)

ATM Tchem Serine-protein kinase ATM (4198 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
PIK3C3 Tchem Phosphatidylinositol 3-kinase catalytic subunit type 3 (535 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: UnknownTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Calculated Properties

Molecular Weight: 339.44Molecular Weight (Monoisotopic): 339.1947AlogP: 2.42#Rotatable Bonds: 4
Polar Surface Area: 48.57Molecular Species: NEUTRALHBA: 4HBD: 1
#RO5 Violations: HBA (Lipinski): 5HBD (Lipinski): 1#RO5 Violations (Lipinski):
CX Acidic pKa: 10.86CX Basic pKa: 4.89CX LogP: 2.37CX LogD: 2.37
Aromatic Rings: 2Heavy Atoms: 25QED Weighted: 0.93Np Likeness Score: -0.75

References

1. Van de Poël A, Toledo-Sherman L, Breccia P, Cachope R, Bate JR, Angulo-Herrera I, Wishart G, Matthews KL, Martin SL, Peacock M, Barnard A, Cox HC, Jones G, McAllister G, Vater H, Esmieu W, Clissold C, Lamers M, Leonard P, Jarvis RE, Blackaby W, Eznarriaga M, Lazari O, Yates D, Rose M, Jang SW, Muñoz-Sanjuan I, Dominguez C..  (2021)  Structure-Based Exploration of Selectivity for ATM Inhibitors in Huntington's Disease.,  64  (8.0): [PMID:33783225] [10.1021/acs.jmedchem.1c00114]

Source